Beyond Numbers: The Value of In-Trial Interview Data for Regulatory and Health Technology Assessment (HTA) Decision-Making
Regulatory health authorities now recognize the significance and value of in-trial qualitative interviews in gaining greater insight into the patient experience. These interviews provide supplementary data that can greatly enhance clinical trial design, interpretation of findings and product value for payers while addressing the unmet needs of patients.
Speakers:
- Carla Dias Barbosa, MSc, senior research leader & in-trial research lead, patient-centered research
- Miriam Kimel, Ph.D., senior research scientist, patient-centered research
- Karen Bailey, Ph.D., research scientist, patient-centered research
- Paulina Rolska-Wójcik, Ph.D., director, value & access consulting
This webinar explores the added value of in-trial interview data in drug development and its pivotal role as a driver in decision-making for regulatory and HTA decisions. Key insights from this webinar include:
- Advantages of utilizing in-trial interview data in drug development
- Use of in-trial data by regulators and health technology assessment (HTA) bodies
- Methodological guidance and current trends
- Recommendations for evidence generation planning
- Opportunities for reimbursement decision-makers
Learn more about conducting qualitative interviews within clinical trials